- Greek Aid Deal ‘Much Better’ Than Euro Exit: Summers
- Bonus Bloodbath: Europe Banker Backlash Continues
- US Trade Deficit Swells to $48.8 Billion on China Gap
- Stocks Looking Past Europe for a New Driver of the Rally
- SEC Reaches Settlement in Bear Stearns Fraud Case
- Israel Likely to Bomb Iran This Year: Political Analyst
- EU Agrees Rules for $700 Trillion Derivatives Market
- The World's Best Beers
- Rep. Bachus Faces Insider Trading Probe: Report
MOST SHARED
- Criminal Probe Trail Going Cold at MF Global
- Greek Aid Deal 'Much Better' Than Euro Exit: Summers
- SEC Reaches Settlement in Bear Stearns Fraud Case
- Global Markets Update: Markets Soften After Failure to Clinch Greek Deal
- Bulls Check In to Community Health
- Jobs You Can Do Forever
- Clint Eastwood: Super Bowl Ad Endorses No One
- Bonus Bloodbath as European Banker Backlash Continues
- Clint Eastwood on Chrysler's Super Bowl Ad
- Larry Summers: Greek Needs Access to Euro
MOST POPULAR
HOT ON FACEBOOK
U.S. Seeks Stronger Warnings For Amylin's Byetta
Text Size 
U.S. health regulators are seeking stronger warnings about the risk of pancreatitis after the deaths of two patients taking Amylin Pharmaceuticals' injectable diabetes drug Byetta, sending the company's shares down as much 16 percent.
 |
CNBC.com |
The Food and Drug Administration Monday said it had received six reports of hemorrhagic or necrotizing pancreatitis requiring hospitalization. Two of the patients died and the four others were recovering at the time of the reports.
The FDA said it was working with Amylin "to add stronger, more prominent warnings in the product label." Amylin co-markets the drug—one of the most successful new diabetes medicines in recent years—with Eli Lilly.
Amylin's shares [AMLN
Loading...
()
] were down about 15 percent at $28.95 in afternoon trading on the Nasdaq, while Eli Lilly's shares [LLY
Loading...
()
] fell 1.7 percent to $47.92 on the New York Stock Exchange.
Pancreatitis is an inflammation of the pancreas, which helps aid in digestion by releasing vital hormones. The condition usually subsides quickly, according to the Merck Manual of Medical Information.
Complications or death are rare, Amylin and Lilly said in a statement. Rates of such problems are about as common in patients taking the drug as in others who have pancreatitis.
In October, the FDA said it had reviewed 30 reports of pancreatitis in patients being treated with Byetta. At the time, Amylin agreed to add information about the risk on its drug label and to alert doctors about the problem.
It was not immediately clear if the FDA would order new so-called "black box'' warnings, the strongest type available, and representatives for the agency could not immediately be reached.
The companies said they would work with the agency to update the drug's label.
- How much did the Facebook founder pay for other shareholders' voting rights? Not a heck of a lot, says the NY Times.
- Here’s a look at Westminster Kennel Club’s most successful breeds and how much they cost.
- When looking for that next career move, workers need to look at the differences between a start-up and a public firm.
- After enduring the recession, many Baby Boomers say money isn’t the most important thing they hope to leave to their kids.
- The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear to accessories and fragrances.
- Attention, online shoppers. The days of tax-free online shopping may be coming to an end in many states.
Data is a real-time snapshot *Data is delayed at least 15 minutes
